RICHMOND, British Columbia, Feb. 25, 2005 (PRIMEZONE) -- As previously disclosed, BioCurex Inc. (Pink Sheets:BOCX) intends to license its technology to companies involved in the manufacture, distribution and sale of cancer diagnostic products. The Company is progressing in its negotiations with third parties with respect to the licensing of two of the Company's products. A Licensing Agreement has not been signed as of this date. The Company will keep investors updated as the situation progresses.
BioCurex is continuing its efforts to advance its exchange listing. Unlike the process involved with listing on the NASDAQ, the AMEX or the NYSE, listing on the OTCBB involves a broker filing a Form 211 with the NASD. All communications pertaining to the 211 Form, supporting documentation and the listing process in general are strictly between the NASD and the broker submitting the 211 Form. Although the Company is not directly involved with the OTCBB listing process, the Company nevertheless cooperates with the broker in supplying answers concerning the Company which may be raised by the NASD. The Company recognizes the advantages of a more senior listing and will advise its investors progressively.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (Pink Sheets:BOCX), visit our website at www.biocurex.com.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.